trastuzumab
information and resources from the National Cancer Institute
trastuzumab
A recombinant humanized monoclonal antibody directed against the human epidermal growth factor receptor 2 (HER2). After binding to HER2 on the tumor cell surface, trastuzumab induces an antibody-dependent cell-mediated cytotoxicity against tumor cells that overexpress HER2. HER2 is overexpressed by many adenocarcinomas, particularly breast adenocarcinomas.trastuzumab
A recombinant humanized monoclonal antibody directed against the human epidermal growth factor receptor 2 (HER2). After binding to HER2 on the tumor cell surface, trastuzumab induces an antibody-dependent cell-mediated cytotoxicity against tumor cells that overexpress HER2. HER2 is overexpressed by many adenocarcinomas, particularly breast adenocarcinomas.
Herceptin Genentech, Inc Dec 11 2001
Herceptin Genentech, Inc Aug 28 2002
Herceptin Genentech, Inc Aug 28 2002
Herceptin
HERCEPTIN as a single agent is indicated for the treatment of patients with metastatic breast cancer whose tumors overexpress the HER2 protein and who have received one or more chemotherapy regimens for their metastatic disease.
Genentech, Inc Sep 25 1998
Herceptin
Herceptin in combination with paclitaxel is indicated for treatment of patients with metastatic breast cancer whose tumors overexpress the HER-2 protein and had not received chemotherapy for their metastatic disease
Genentech, Inc Feb 09 2000
|
|
|
|
news articles
[an error occurred while processing this directive][an error occurred while processing this directive] |
|
